1
|
Jácome-Pita F, Sánchez-Salas R, Barret E,
Amaruch N, Gonzalez-Enguita C and Cathelineau X: Focal therapy in
prostate cancer, The current situation. Ecancermedicalscience.
8:4352014.PubMed/NCBI
|
2
|
Roudier MP, True LD, Higano CS, Vesselle
H, Ellis W, Lange P and Vessella RL: Phenotypic heterogeneity of
end-stage prostate carcinoma metastatic to bone. Hum Pathol.
34:646–653. 2003. View Article : Google Scholar : PubMed/NCBI
|
3
|
Georgescu MM, Cote G, Agarwal NK and White
CL III: NHERF1/EBP50 controls morphogenesis of 3D colonic glands by
stabilizing PTEN and ezrin-radixin-moesin proteins at the apical
membrane. Neoplasia. 16:e1–e2. 2014. View Article : Google Scholar
|
4
|
Takahashi Y, Morales FC, Kreimann EL and
Georgescu MM: PTEN tumor suppressor associates with NHERF proteins
to attenuate PDGF receptor signaling. EMBO J. 25:910–920. 2006.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Molina JR, Agarwal NK, Morales FC, Hayashi
Y, Aldape KD, Cote G and Georgescu MM: PTEN, NHERF1 and PHLPP form
a tumor suppressor network that is disabled in glioblastoma.
Oncogene. 31:1264–1274. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Bartholow TL, Becich MJ, Chandran UR and
Parwani AV: Immunohistochemical analysis of
ezrin-radixin-moesin-binding phosphoprotein 50 in prostatic
adenocarcinoma. BMC Urol. 11:122011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Prajapati A and Gupta S, Mistry B and
Gupta S: Prostate stem cells in the development of benign prostate
hyperplasia and prostate cancer, Emerging role and concepts. Biomed
Res Int. 2013:1079542013. View Article : Google Scholar : PubMed/NCBI
|
8
|
International Organization for
Standardization (ISO): ISO 10993-5: Biological evaluation of
medical devices - Part 5: Tests for in vitro cytotoxicity. ISO.
Geneva: 2009.
|
9
|
Malfettone A, Saponaro C, Paradiso A,
Simone G and Mangia A: Peritumoral vascular invasion and NHERF1
expression define an immunophenotype of grade 2 invasive breast
cancer associated with poor prognosis. BMC Cancer. 12:1062012.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Bellizzi A, Malfettone A, Cardone RA and
Mangia A: NHERF1/EBP50 in Breast Cancer, Clinical Perspectives.
Breast Care (Basel). 5:86–90. 2010. View Article : Google Scholar : PubMed/NCBI
|
11
|
Curto M, Cole BK, Lallemand D, Liu CH and
McClatchey AI: Contact-dependent inhibition of EGFR signaling by
Nf2/Merlin. J Cell Biol. 177:893–903. 2007. View Article : Google Scholar : PubMed/NCBI
|
12
|
James MF, Beauchamp RL, Manchanda N,
Kazlauskas A and Ramesh V: NHERF binding site links the betaPDGFR
to the cytoskeleton and regulates cell spreading and migration. J
Cell Sci. 117:2951–2961. 2004. View Article : Google Scholar : PubMed/NCBI
|
13
|
Malavaki CJ, Roussidis AE, Gialeli C,
Kletsas D Tsegenidis, et al: Imatinib as a key inhibitor of the
platelet-derived growth factor receptor mediated expression of cell
surface heparan sulfate proteoglycans and functional properties of
breast cancer cells. FEBS J. 280:2477–2489. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Yao W, Feng D, Bian W, Yang L, Li Y, Yang
Z, Xiong Y, Zheng J, Zhai R and He J: EBP50 inhibits EGF-induced
breast cancer cell proliferation by blocking EGFR phosphorylation.
Amino Acids. 43:2027–2035. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Jiang Y, Wang S, Holcomb J, Trescott L,
Guan X, Hou Y, Brunzelle J, Sirinupong N, Li C and Yang Z:
Crystallographic analysis of NHERF1-PLCβ3 interaction provides
structural basis for CXCR2 signaling in pancreatic cancer. Biochem
Biophys Res Commun. 446:638–643. 2014. View Article : Google Scholar : PubMed/NCBI
|
16
|
Mamlouk S, Kalucka J, Singh RP, Franke K,
Muschter A, Langer A, Jakob C, Gassmann M, Baretton GB and Wielockx
B: Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes
impairs tumor development. Int J Cancer. 134:849–858. 2014.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Chen Q, Lu HS, Gan MF, Chen LX, He K, Fan
GM and Cao XQ: Expression and prognostic role of MEKK3 and pERK in
patients with renal clear cell carcinoma. Asian Pac J Cancer Prev.
16:2495–2499. 2015. View Article : Google Scholar : PubMed/NCBI
|
18
|
Tatsuta T, Sugawara S, Takahashi K, Ogawa
Y, Hosono M and Nitta K: Cancer-selective induction of apoptosis by
leczyme. Front Oncol. 4:1392014. View Article : Google Scholar : PubMed/NCBI
|
19
|
Kreimann EL, Morales FC, de Orbeta-Cruz J,
Takahashi Y, Adams H, et al: Cortical stabilization of beta-catenin
contributes to NHERF1/EBP50 tumor suppressor function. Oncogene.
26:5290–5299. 2007. View Article : Google Scholar : PubMed/NCBI
|